Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma

By sjmartinez • February 6, 2024

Lebacle C, Pooli A, Shuch B, Rao N, Chamie K, Kroeger N, Faiena I, Liu S, Wood EL, Belldegrun A, Drakaki A, Pantuck AJ. Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma. Cancer Invest. 2024 Feb 5:1-7. doi: 10.1080/07357907.2024.2308172. Epub ahead of print. PMID: 38314786.

Tags: 5q chromosome, adjuvant treatment, cytogenetic, Fellow, follow-up, Hematology/Oncology, Publications, Renal cell carcinoma

daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

Paulson S, Ikeda M, Shen L, Stein A, Macarulla T, Milella M, Golan T, Wainberg Z, Taieb J, Wang L, Polydoros F, Abecunas C, López[...]

Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies

Berkowitz MJ, Arzoo KK. Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies. Cureus. 2026 Oct 6;18(10):e117545. doi: 10.7759/cureus.117545. PMID: 42992212; PMCID:[...]

PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1-positive NSCLC

Altan M, Navani V, Kim HR, Sun L, Paz-Ares L, Chmielewska I, Lin CC, Cuppens K, Mountzios I, Peled N, Cappuzzo F, Wang B, Zhou[...]